PMID- 25887125
OWN - NLM
STAT- MEDLINE
DCOM- 20160210
LR  - 20181202
IS  - 1471-2490 (Electronic)
IS  - 1471-2490 (Linking)
VI  - 15
DP  - 2015 Apr 16
TI  - Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell 
      carcinoma: a single-institution experience in Japan.
PG  - 32
LID - 10.1186/s12894-015-0027-4 [doi]
LID - 32
AB  - BACKGROUND: Clinical benefit of axitinib as a first line agent to treat patients 
      with metastatic renal cell carcinoma (mRCC), or locally advanced renal cell 
      carcinoma (RCC) have not been clearly demonstrated. The aim of this study was to 
      evaluate the efficacy and safety of axitinib as first-line therapy in Japanese 
      patients with locally advanced RCC or mRCC. METHODS: In this retrospective study, 
      we focused on eighteen patients who underwent first-line therapy with axitinib 
      between May 2012 and May 2014 at Hirosaki University. Axitinib was orally 
      administered at a dose of 10 mg daily. Progression-free survival (PFS) was the 
      primary endpoint, while secondary endpoints included overall response rate (ORR) 
      and adverse events (AEs). RESULTS: All patients had histologically proven clear 
      cell RCC. The median duration of the administration of axitinib was 10.8 months. 
      According to the response evaluation criteria for solid tumors, five patients 
      (27.8%) achieved a partial response and nine (50%) had stable disease. The 1-year 
      PFS rate was 84.4%, and the median PFS was 20.4 months (95% confidence interval, 
      17.5 - 21.7). No serious AEs were reported during the study, and there were no 
      toxicity-related deaths. CONCLUSIONS: In the current study, axitinib showed 
      acceptable oncological outcomes and favorable safety profile as first-line 
      therapy for locally advanced RCC or mRCC in treatment-naive Japanese patients. 
      Thus, first-line therapy with axitinib may provide a feasible option for 
      treatment of advanced RCC or mRCC patients.
FAU - Koie, Takuya
AU  - Koie T
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, 036-8562, Japan. goodwin@cc.hirosaki-u.ac.jp.
FAU - Ohyama, Chikara
AU  - Ohyama C
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, 036-8562, Japan. coyama@cc.hirosaki-u.ac.jp.
FAU - Yoneyama, Takahiro
AU  - Yoneyama T
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, 036-8562, Japan. uroyone@cc.hirosaki-u.ac.jp.
FAU - Yamamoto, Hayato
AU  - Yamamoto H
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, 036-8562, Japan. ha-yama@cc.hirosaki-u.ac.jp.
FAU - Imai, Atsushi
AU  - Imai A
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, 036-8562, Japan. tsushi.imai@gmail.com.
FAU - Hatakeyama, Shingo
AU  - Hatakeyama S
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, 036-8562, Japan. shingorilla2@gmail.com.
FAU - Hashimoto, Yasuhiro
AU  - Hashimoto Y
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, 036-8562, Japan. y-hashi@cc.hirosaki-u.ac.jp.
FAU - Yoneyama, Tohru
AU  - Yoneyama T
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, 036-8562, Japan. tohruyon@cc.hirosaki-u.ac.jp.
FAU - Tobisawa, Yuki
AU  - Tobisawa Y
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, 036-8562, Japan. tobisawa@cc.hirosaki-u.ac.jp.
FAU - Mori, Kazuyuki
AU  - Mori K
AD  - Department of Urology, Hirosaki University Graduate School of Medicine, 5 
      Zaifucho, Hirosaki, 036-8562, Japan. moribio@cc.hirosaki-u.ac.jp.
LA  - eng
PT  - Journal Article
DEP - 20150416
PL  - England
TA  - BMC Urol
JT  - BMC urology
JID - 100968571
RN  - 0 (Imidazoles)
RN  - 0 (Indazoles)
RN  - 0 (Protein Kinase Inhibitors)
RN  - C9LVQ0YUXG (Axitinib)
SB  - IM
MH  - Aged
MH  - Axitinib
MH  - Carcinoma, Renal Cell/*drug therapy/secondary/surgery
MH  - Female
MH  - Humans
MH  - Imidazoles/*therapeutic use
MH  - Indazoles/*therapeutic use
MH  - Kidney Neoplasms/*drug therapy/secondary/surgery
MH  - Male
MH  - Middle Aged
MH  - Nephrectomy
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC4417199
EDAT- 2015/04/19 06:00
MHDA- 2016/02/11 06:00
PMCR- 2015/04/16
CRDT- 2015/04/19 06:00
PHST- 2014/09/29 00:00 [received]
PHST- 2015/04/07 00:00 [accepted]
PHST- 2015/04/19 06:00 [entrez]
PHST- 2015/04/19 06:00 [pubmed]
PHST- 2016/02/11 06:00 [medline]
PHST- 2015/04/16 00:00 [pmc-release]
AID - 10.1186/s12894-015-0027-4 [pii]
AID - 27 [pii]
AID - 10.1186/s12894-015-0027-4 [doi]
PST - epublish
SO  - BMC Urol. 2015 Apr 16;15:32. doi: 10.1186/s12894-015-0027-4.